During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL). According to the Magrath staging system, patients were classified as low and high risk. Low-risk received three cycles of the CODOX-M regimen; high-risk patients received four alternating cycles with the CODOX-M and IVAC regimens. Thirty-five patients entered the study: 32 (91%) achieved complete remission (CR); three were non-responders and died and one patient died in CR. Two responders relapsed after 2 months and one presented early B acute lymphoblastic leukemia 33 months from the end of therapy. The 5-year overall survival and event free-survival are 83% and 80%, respectively. No late toxicity was registered. In our experience with a median follow-up of 11 years, the NCI 89-C-41 protocol has confirmed its high cure rate in BLL and DLBCL children and adolescents.

CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: A 15-year monocentric experience / Moleti, Ml; Testi, Anna Maria; Giona, Fiorina; Malandruccolo, L; Pescarmona, Edoardo; Martino, P; Paoloni, F; Barberi, Walter; Palumbo, G; Mandelli, Franco; Foa, Roberto. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 48(3):(2007), pp. 551-559. [10.1080/10428190601078944]

CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: A 15-year monocentric experience.

TESTI, Anna Maria;GIONA, Fiorina;PESCARMONA, Edoardo;BARBERI, Walter;MANDELLI, Franco;FOA, Roberto
2007

Abstract

During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL). According to the Magrath staging system, patients were classified as low and high risk. Low-risk received three cycles of the CODOX-M regimen; high-risk patients received four alternating cycles with the CODOX-M and IVAC regimens. Thirty-five patients entered the study: 32 (91%) achieved complete remission (CR); three were non-responders and died and one patient died in CR. Two responders relapsed after 2 months and one presented early B acute lymphoblastic leukemia 33 months from the end of therapy. The 5-year overall survival and event free-survival are 83% and 80%, respectively. No late toxicity was registered. In our experience with a median follow-up of 11 years, the NCI 89-C-41 protocol has confirmed its high cure rate in BLL and DLBCL children and adolescents.
01 Pubblicazione su rivista::01a Articolo in rivista
CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: A 15-year monocentric experience / Moleti, Ml; Testi, Anna Maria; Giona, Fiorina; Malandruccolo, L; Pescarmona, Edoardo; Martino, P; Paoloni, F; Barberi, Walter; Palumbo, G; Mandelli, Franco; Foa, Roberto. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 48(3):(2007), pp. 551-559. [10.1080/10428190601078944]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/362823
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 6
social impact